Apium Additive Technologies resumes search for investors

The Karlsruhe-based 3D printer manufacturer Apium Additive Technologies has resumed its search for investors.

The aim is to focus more on the medical sector and to qualify the latest product platform, the Apium P400, for this purpose. Managing Director Lars Pfotzer emphasized the need for fresh capital:

“We are already successfully serving the industrial and medical markets worldwide with our existing 3D printers and would like to focus more on the medical sector. To this end, we want to qualify our latest product platform, the Apium P400 industrial 3D printer, which we have developed to market maturity in recent years, for the medical target market. To do this, we need fresh capital to enable us to take this step. Then we can reap the rewards of our development work over the past few months. However, our current investor is unable to provide any additional funds for this. We have therefore decided to restructure our young company in insolvency proceedings and resume the search for investors.”

Apium positions itself as a manufacturer of machine tools whose patented technology enables the processing of high-performance thermoplastics. This technology creates high-strength components that are particularly suitable for the production of medical implants. Customers are already using Apium’s 3D printers to produce customized implant solutions based on CT/MRI data, leading to faster treatment success. Medical research institutes are also using Apium’s products to develop materials and components that can later be used in clinical practice.

“I see great potential for Apium if an investor can be found to support the young company. The high cost of development work has meant that Apium is unable to fully exploit its potential in terms of market development and the further development of its products under the current ownership structure. The current provisional insolvency proceedings offer investors the opportunity to take over the company free of legacy burdens and lead it into the future,” says the provisional insolvency administrator appointed by the Karlsruhe Local Court, Holger Blümle from the Karlsruhe office of the nationwide law firm Schultze & Braun.

Founded in 2016, the start-up currently employs 15 people and recently achieved an annual turnover of around one million euros. Despite its potential, the company has run into financial difficulties due to high development costs. The provisional insolvency proceedings, ordered by Karlsruhe Local Court, are intended to offer investors the opportunity to take over Apium free of legacy burdens.

“Our aim is to enter into negotiations with potential investors as soon as possible in order to be able to release Apium from the proceedings quickly,” says the provisional insolvency administrator Holger Blümle.

Business operations will remain unaffected during the insolvency proceedings and the aim is to enter into negotiations with potential investors as soon as possible. Initial expressions of interest have already been received, which gives hope for an early solution and further development of Apium in the medical sector.